Cargando…

Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer

[Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Zheng, Sergeeva, Olga, Roelle, Sarah, Cheng, Han, Gao, Songqi, Li, Yajuan, Lee, Zhenghong, Lu, Zheng-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356864/
https://www.ncbi.nlm.nih.gov/pubmed/30729224
http://dx.doi.org/10.1021/acsomega.8b02729
_version_ 1783391657284075520
author Han, Zheng
Sergeeva, Olga
Roelle, Sarah
Cheng, Han
Gao, Songqi
Li, Yajuan
Lee, Zhenghong
Lu, Zheng-Rong
author_facet Han, Zheng
Sergeeva, Olga
Roelle, Sarah
Cheng, Han
Gao, Songqi
Li, Yajuan
Lee, Zhenghong
Lu, Zheng-Rong
author_sort Han, Zheng
collection PubMed
description [Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe consists of a small ZD2 peptide specific to EDB-FN and a (64)Cu-DOTA chelate. The probe was synthesized using standard solid-phase peptide chemistry and chelated to (64)Cu prior to imaging. PET images were acquired at 4 and 22 h after intravenously injecting a 200 μCi probe into mice bearing human PC3 and LNCaP tumors, which represent highly aggressive and slow-growing prostate tumors, respectively. At 4 and 22 h postinjection, tumors could be clearly identified in the PET images. A significant higher signal was observed in PC3 tumors than in LNCaP tumors at 22 h (p = 0.01). Probe accumulation was also higher in PC3 tumors at 24 h. These data demonstrated that PET molecular imaging of EDB-FN in the tumor microenvironment of prostate cancer allows efficient differentiation of PC3 and LNCaP tumors in vivo. The ZD2 peptide-targeted PET probe shows potential in the detection and characterization of high-risk prostate cancer to improve the clinical management of prostate cancer.
format Online
Article
Text
id pubmed-6356864
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-63568642019-02-04 Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer Han, Zheng Sergeeva, Olga Roelle, Sarah Cheng, Han Gao, Songqi Li, Yajuan Lee, Zhenghong Lu, Zheng-Rong ACS Omega [Image: see text] Positron emission tomography (PET) is a sensitive modality for cancer molecular imaging. We aim to develop a PET probe for sensitive detection and risk stratification of prostate cancer by targeting an abundant microenvironment oncoprotein, extradomain-B fibronectin (EDB-FN). The probe consists of a small ZD2 peptide specific to EDB-FN and a (64)Cu-DOTA chelate. The probe was synthesized using standard solid-phase peptide chemistry and chelated to (64)Cu prior to imaging. PET images were acquired at 4 and 22 h after intravenously injecting a 200 μCi probe into mice bearing human PC3 and LNCaP tumors, which represent highly aggressive and slow-growing prostate tumors, respectively. At 4 and 22 h postinjection, tumors could be clearly identified in the PET images. A significant higher signal was observed in PC3 tumors than in LNCaP tumors at 22 h (p = 0.01). Probe accumulation was also higher in PC3 tumors at 24 h. These data demonstrated that PET molecular imaging of EDB-FN in the tumor microenvironment of prostate cancer allows efficient differentiation of PC3 and LNCaP tumors in vivo. The ZD2 peptide-targeted PET probe shows potential in the detection and characterization of high-risk prostate cancer to improve the clinical management of prostate cancer. American Chemical Society 2019-01-14 /pmc/articles/PMC6356864/ /pubmed/30729224 http://dx.doi.org/10.1021/acsomega.8b02729 Text en Copyright © 2019 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Han, Zheng
Sergeeva, Olga
Roelle, Sarah
Cheng, Han
Gao, Songqi
Li, Yajuan
Lee, Zhenghong
Lu, Zheng-Rong
Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title_full Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title_fullStr Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title_full_unstemmed Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title_short Preparation and Evaluation of ZD2 Peptide (64)Cu-DOTA Conjugate as a Positron Emission Tomography Probe for Detection and Characterization of Prostate Cancer
title_sort preparation and evaluation of zd2 peptide (64)cu-dota conjugate as a positron emission tomography probe for detection and characterization of prostate cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356864/
https://www.ncbi.nlm.nih.gov/pubmed/30729224
http://dx.doi.org/10.1021/acsomega.8b02729
work_keys_str_mv AT hanzheng preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT sergeevaolga preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT roellesarah preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT chenghan preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT gaosongqi preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT liyajuan preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT leezhenghong preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer
AT luzhengrong preparationandevaluationofzd2peptide64cudotaconjugateasapositronemissiontomographyprobefordetectionandcharacterizationofprostatecancer